HealthQuill Obesity
Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease, the company announced.
Drugs Health Pharma

Novo to buy Akero for $5.2 billion, to pocket trial liver disease drug

Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease,.

Read More
Pfizer Inc., a US pharmaceutical company founded in 1849, has signed an agreement with the Trump administration to lower prices of prescription medicines in the North American nation
Drugs Medical Pharma

Pfizer inks deal with Trump to lower price of prescription drugs in US

Pfizer Inc., a US pharmaceutical company founded in 1849, has signed an agreement with the Trump administration to lower prices of prescription medicines.

Read More
Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after it scrapped development of its own weight-loss pill in April this year.
Drugs Health Pharma

Pfizer to buy Matsera Inc. for $7.3 billion, eyes 4 anti-obesity drugs

Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after.

Read More
Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its metabolic disease portfolio.
Drugs Health Pharma

Roche to buy 89bio Inc for $3.5 billion to expand metabolic disease portfolio

Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its.

Read More
A 15-minute fast walk helped reduce mortality by 20%, mostly in low-income Black individuals in the US, a study finds.
Health Medical Research

A 15-minute brisk walk may cut mortality rate by 20%: Vanderbilt

A 15-minute fast walk helped reduce mortality by 20%, mostly in low-income Black individuals in the US, a study finds.

Read More
Novo Nordisk A/S has sought approval from the European Medicines Agency for a higher dose of its weight-loss drug Wegovy, after trial data showed a third of participants losing 25% of their body weight.
Drugs Health Pharma

Novo Nordisk seeks EU nod for higher dose of its weight-loss drug Wegovy

HQ Team July 8, 2025: Novo Nordisk A/S has sought approval from the European Medicines Agency for a higher dose of its weight-loss.

Read More
Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants, showed patients lost about 23% of their body weight compared to a dummy group’s 2-3%.
Drugs Health Pharma

Novo Nordisk’s obesity drug CagriSema cuts weight by 23%

HQ Team June 22, 2025: Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants,.

Read More
Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their weight in a small study, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s amycretin drug helps obese adults lose 24% weight

HQ Team June 21, 2025: Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their.

Read More
Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials in people with obesity compared to a dummy drug, the company stated.
Drugs Health Pharma

Wegovy’s weight-loss efficacy improves with higher dosage

HQ Team June 21, 2025: Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials.

Read More
Denmark’s Novo Nordisk will advance its experimental drug amycretin, in both injection and oral forms, into end-stage trials in weight management based on completed clinical studies, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s obesity drug to begin end-stage trials in early 2026

HQ Team July 13, 2025: Denmark’s Novo Nordisk A/S will advance its experimental drug amycretin, in both injection and oral forms, into end-stage.

Read More